This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.02116-07v1 46/3/933    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Borman, A. M. Articles by Johnson, E. M. PubMed PubMed Citation Articles by Borman, A. M. Articles by Johnson, E. M.

Candida nivariensis, an Emerging Pathogenic Fungus with Multidrug Resistance to Antifungal Agents

Mycology Reference Laboratory, Health Protection Agency, Bristol,¹ Department of Pathology and Microbiology, University of Bristol, Bristol,² British Antarctic Survey, Cambridge, United Kingdom³

Received 2 November 2007/ Returned for modification 13 December 2007/ Accepted 6 January 2008

In 2005, Candida nivariensis, a yeast species genetically related to Candida glabrata, was described following its isolation from three patients in a single Spanish hospital. Between 2005 and 2006, 16 fungal isolates with phenotypic similarities to C. nivariensis were submitted to the United Kingdom Mycology Reference Laboratory for identification. The strains originated from various clinical specimens, including deep, usually sterile sites, from patients at 12 different hospitals in the United Kingdom. PCR amplification and sequencing of the D1D2 and internal transcribed spacer 1 (ITS1) regions of the nuclear ribosomal gene cassette confirmed that these isolates from the United Kingdom are genetically identical to C. nivariensis. Biochemically, C. glabrata and C. nivariensis are distinguished by their differential abilities to assimilate trehalose. However, in contrast to the original published findings, we found that C. glabrata isolates, but not C. nivariensis isolates, are capable of assimilating this substrate. Antifungal susceptibility tests revealed that C. nivariensis isolates are less susceptible than C. glabrata isolates to itraconazole, fluconazole, and voriconazole and to have significantly higher flucytosine MICs than C. glabrata strains. Finally, C. nivariensis could be rapidly distinguished from the other common pathogenic fungus species by pyrosequencing of the ITS2 region. In the light of these data, we believe that C. nivariensis should be regarded as a clinically important emerging pathogenic fungus.

Published ahead of print on 16 January 2008.